Columbia Laboratories, Inc. To Discuss Fourth Quarter And Year End 2013 Financial Results On March 5 Conference Call
Published: Feb 26, 2014
BOSTON, Feb. 26, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 5, 2014, to discuss financial results of the fourth quarter and fiscal year ended December 31, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows:
Wednesday, March 5, 2014
8:30 am EST
Toll free: (877) 870-4263 (U.S.) or (855) 669-9657 (Canada)
International: (412) 317-0790
Webcast (live & archive):
The teleconference replay will be available approximately one hour after completion through Tuesday, March 11, 2014, at (877) 344-7529 (U.S.) or (412) 317-0088 (International). The conference ID for the replay is 10040650. The archived webcast will be available for one year via the aforementioned URLs.
About Columbia Laboratories
Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry. The Company has a successful heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery. Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide. For more information, please visit www.columbialabs.com.
CRINONE® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S.
Jonathan Lloyd Jones
Vice President & CFO
Senior Vice President
Columbia Laboratories, Inc.
The Trout Group LLC
SOURCE Columbia Laboratories, Inc.
Help employers find you! Check out all the jobs and post your resume.